Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDQuarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2025 | 8 | -$3.43 | -$2.82 | -$3.11 |
Q2 2025 | 6 | -$4.47 | -$1.85 | -$3.04 |
Q3 2025 | 4 | -$2.41 | -$1.00 | -$1.64 |
Q4 2025 | 6 | -$3.23 | -$1.34 | -$2.20 |
Q1 2026 | 3 | -$3.96 | -$1.64 | -$2.70 |
Q2 2026 | 5 | -$4.01 | -$1.66 | -$2.73 |
Q3 2026 | 3 | -$1.35 | -$0.56 | -$0.92 |
Q4 2026 | 5 | -$2.22 | -$0.92 | -$1.51 |
Moderna, Inc. last posted its earnings results on Friday, February 14th, 2025. The company reported $-2.5 earnings per share for the quarter, topping analysts' consensus estimates of $-2.68 by $0.18. The company had revenue of 966.00 M for the quarter and had revenue of 3.24 B for the year. Moderna, Inc. has generated $-9 earnings per share over the last year ($-9.27 diluted earnings per share) and currently has a price-to-earnings ratio of -3.79. Moderna, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 20th, 2025 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
02/21/2025 | Q4 2024 | N/A | -$2.91 | N/A | $942.82 M | $966.00 M |
11/07/2024 | Q3 2024 | -$1.91 | $0.03 | 1.94 | $1.25 B | $1.86 B |
08/01/2024 | Q2 2024 | -$3.35 | -$3.33 | 0.02 | $128.41 M | $241.00 M |
05/02/2024 | Q1 2024 | -$3.56 | -$3.08 | 0.48 | N/A | $167.00 M |
02/23/2024 | Q4 2023 | N/A | $0.57 | N/A | $2.51 B | $2.81 B |
11/03/2023 | Q3 2023 | N/A | -$9.53 | N/A | $1.38 B | $1.83 B |
08/03/2023 | Q2 2023 | -$3.84 | -$3.62 | 0.22 | $307.67 M | $344.00 M |
05/04/2023 | Q1 2023 | -$1.77 | $0.20 | 1.97 | N/A | $1.86 B |
02/24/2023 | Q4 2022 | N/A | $3.81 | N/A | N/A | $5.08 B |
11/03/2022 | Q3 2022 | $3.29 | $2.53 | -0.76 | $3.53 B | $3.22 B |
08/03/2022 | Q2 2022 | $4.55 | $5.24 | 0.69 | $4.10 B | $4.57 B |
05/04/2022 | Q1 2022 | $5.21 | $8.58 | 3.37 | N/A | $5.94 B |
02/25/2022 | Q4 2021 | N/A | $12.03 | N/A | N/A | $6.95 B |
11/04/2021 | Q3 2021 | $9.05 | $8.27 | -0.78 | $6.08 B | $4.83 B |
08/05/2021 | Q2 2021 | $5.96 | $6.93 | 0.97 | $4.21 B | $4.22 B |
05/06/2021 | Q1 2021 | $2.39 | $3.05 | 0.66 | N/A | $1.74 B |
02/26/2021 | Q4 2020 | N/A | -$0.69 | N/A | N/A | $229.38 M |
10/30/2020 | Q3 2020 | N/A | -$0.59 | N/A | $80.60 M | $12.22 M |
08/06/2020 | Q2 2020 | N/A | -$0.31 | N/A | $27.51 M | $28.44 M |
05/07/2020 | Q1 2020 | -$0.37 | -$0.35 | 0.02 | N/A | $4.46 M |
Moderna, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 20th, 2025 based offlast year's report dates.
In the previous quarter, Moderna, Inc. (:MRNA) reported $-2.5 earnings per share (EPS) to beat the analysts' consensus estimate of $-2.68 by $0.18.
The conference call for Moderna, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Moderna, Inc.'s latest earnings report can be read online.
Moderna, Inc. (:MRNA) has a recorded annual revenue of $3.24 B.
Moderna, Inc. (:MRNA) has a recorded net income of $-3,561,000,000.Moderna, Inc. has generated $-9.27 earnings per share over the last four quarters.
Moderna, Inc. (:MRNA) has a price-to-earnings ratio of -3.79 and price/earnings-to-growth ratio is 0.06.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED